VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

News >

Sacituzumab Govitecan Shows Promise in Urothelial Cancer

Angelica Welch
Published: Thursday, Mar 23, 2017

Scott Tagawa, MD

Scott Tagawa, MD

The antibody-drug conjugate sacituzumab govitecan (IMMU-132) had an overall response rate of 31% in heavily pretreated patients with metastatic urothelial cancer, according to updated phase II study findings presented earlier this year at the 2017 Genitourinary Cancers Symposium.

The responses occurred in 11 of 36 evaluable patients and included 1 complete response and 10 partial responses. The median progression-free survival (PFS) was 7.2 months (95% CI, 6.7-11.7) and the median overall survival (OS) was 15.5 months (95% CI, 8.9-17.2).

The researchers considered the drug to be well tolerated. Grade 3 or higher adverse events included neutropenia (30%), febrile neutropenia (11%), fatigue (11%), and diarrhea (3%).

Sacituzumab govitecan consists of the active metabolite of irinotecan, SN-38, linked with a humanized IgG antibody targeted against TROP-2, a cell-surface glycoprotein.

In an interview with OncLive, lead study author Scott Tagawa, MD, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discussed the latest findings with sacituzumab govitecan in patients with metastatic urothelial cancer.

OncLive: What were the latest results from this trial?

Tagawa: This is an update of the phase II portion of a phase I/II trial. Of about 40 patients participating, 36 are evaluable for response—which is the primary endpoint. With the increased numbers, the response rate has held up and remains above 30%. This is a nice benchmark against historical chemotherapy in patients who were pretreated with chemotherapy, as it is pretty rare to get a response rate above 10%.

Besides just having a nice objective response rate, the intent-to-treat analysis included patients who didn't necessarily make it to a scan or have early progression. The overall intent-to-treat analysis showed that progression-free survival is above 7 months and overall survival above 15 months, which goes hand-in-hand with the response rate.

Overall, it’s a well-tolerated drug. And, as I am speaking right now, I have a patient in New York receiving month 20 of therapy, so he's had, essentially, a complete response in his liver, and has tolerated therapy for 20 months. We see myelosuppression, that being the dose-limiting toxicity, but it’s completely manageable. 

With an ADC, we'd expect more delivery to the tumor area, and less systemically. Some of the side effects we might see with irinotecan, such as diarrhea, is generally grade 1, occasionally grade 2 [with Sacituzumab govitecan]. So, I think in concept, the ADC delivering more to the tumor—or the tumor area in this case—and less to the systemic circulation, holds up with the ADC.

Even though preliminary, the objective response rates, and progression-free and overall survival all look impressive versus historical control. So, I think ADCs are one additional exciting modality of therapy.

What are the next steps with sacituzumab govitecan?

The next step would be to complete the total phase II trial, so we are close. We hope to have completion of enrollment within the next couple of months and then have the final results later in the year. 

If the results hold up, we would call this a positive phase II trial and that would set the stage for a phase III trial, which we've talked about but haven't fully designed yet.

What other treatments, including immunotherapy, are emerging in the landscape of urothelial carcinoma?

Broadly, in the terms of metastatic urothelial carcinoma, we've had platinum-based therapy for a long period of time. I think some people forget that about 1 in 10 patients, historically, have had long-term or disease control or cures just with platinum-based chemotherapy. So, I think that remains important to remember. 

What has moved from "very exciting" to primetime, are checkpoint inhibitors, with the approval of a couple agents recently, and more coming in 2017. Specifically, PD-1 and PD-L1 antibodies are very nice because they are generally very well tolerated. Those patients that respond can have a very durable response, whether they remain on therapy or not.

The unfortunate part is that it is only around a quarter of all patients that do respond, so we'd like to work on that with biomarkers to select patients, as well as a way to increase the number of patients who respond. But now the unmet need is beyond just platinum-based therapy and a single PD-1 or PD-L1 antibody. 

What I find exciting are several ADCs—IMMU-132 being one—that have now treated above 40 patients. So, I find that as a group, they all seem to be fairly well tolerated. They are all nonrandomized trials, but this is compared to historical controls of chemotherapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x